Attractive Pickering emulsion gel loaded with oxaliplatin and lactate dehydrogenase inhibitor increases the anti-tumor effect in hepatocellular carcinoma

• Published in: Chinese chemical letters p. 110519
• Main Authors: Ye, Chanqi, Zhang, Jia, Shen, Jie, Chen, Ruyin, Li, Qiong, Zhao, Peng, Chen, Dong, Ruan, Jian
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.09.2024
• Subjects: Anti-tumor therapy; Drug delivery; Immune activation; Lactate dehydrogenase A; Oxaliplatin; Drug delivery; Immune activation; Oxaliplatin; Anti-tumor therapy; Lactate dehydrogenase A
• ISSN: 1001-8417
• DOI: 10.1016/j.cclet.2024.110519

Oxaliplatin (OXA) can be used as a palliative treatment for advanced hepatocellular carcinoma (HCC). While most patients still have rapid disease progression after OXA due to the drug resistance. The lactate dehydrogenase A (LDHA) inhibitors can reduce the inflammation-induced effects, metastasis, and proliferation potential of cancer cells. Here, we adopt the water-in-oil attractive Pickering emulsion gel (APEG) to deliver OXA and LDHA inhibitor, GSK2837808A (GSK). OXA is dissolved in water and GSK is dissolved in iodized oil. This drugs-loaded APEG has good biocompatibility and can release OXA and GSK slowly. OXA + GSK@gel has significant anti-tumor effect on HCC model, which can effectively inhibit tumor cell proliferation and promote tumor cell apoptosis. Meanwhile, flow analysis confirm that it could activate the tumor immune microenvironment in HCC. The infiltration of CD8+ T cells is increased, thereby providing better anti-tumor effect. The results suggest that the APEGs loaded with OXA and GSK can effectively improve the delivery efficiency and enhance the anti-tumor therapy. Here, we adopt the water-in-oil attractive Pickering emulsion gel (APEG) to deliver oxaliplatin and lactate dehydrogenase A inhibitor, which can effectively improve the delivery efficiency and enhance the anti-tumor therapy. [Display omitted]